Andrew D. Skibo is Head of Global Biologics Operations at MedImmune / AstraZeneca where he affects changes in manufacturing operations, quality oversight, and cross-functional relations throughout the company. Previously he has worked in other senior leadership roles at Amgen, Genentech, and Foster Wheeler, among others. In these roles, he has been responsible for significant aspects of the companies’ operations including operations, engineering, construction, and validation for large-scale capital projects related to bio-pharmaceutical manufacturing. He is a Chairman of the Global Pharmaceutical Manufacturers Leadership Forum (GPMLF), a member of the Materials Technical Advisory Committee of the US Department of Commerce, and a member of the Editorial Advisory Board of Life Science Leader. As an ISPE Member for 27 years Andy Skibo has served on the judging panel for the Facility of the Year Award, he has been a conference leader, and he participates on several committees. He was elected to the ISPE International Board of Directors in 2011 and served as Chairman of the Board of Directors in 2014-2015. He serves as a Non-Executive Director on the Board of a major international engineering and construction firm. Andy Skibo holds a BS in Organic Chemistry and an MS in Chemical Engineering, both from MIT.